You are here

PrEP on hold

A decision to subsidise PrEP has been deferred, much to the disappointment of HIV advocates. “Given PrEP is so effective at preventing HIV transmission, people will be disappointed and deeply frustrated at this outcome,” said Darryl O’Donell, CEO of the Australian Federation of AIDS Organisations (AFAO).

Drug companies Mylan and Gilead Sciences both brought applications for PrEP before the Pharmaceutical Benefits Advisory Committee (PBAC) which has decided to hold off on a decision while it seeks further information on the number of people likely to use PrEP and conducts price negotiations.

Approximately 31,000 Australian gay and bisexual men are at high risk of HIV and would benefit from PrEP’s listing on the Pharmaceutical Benefits Scheme (PBS). AFAO, along with other HIV organisations, recommends that the two drug companies and PBAC fast-track negotiations as a matter of urgency. “HIV will be needlessly transmitted while we wait for equitable and affordable access to PrEP,” said O’Donnell.

Robert Mitchell, Vice-President of the National Association of People with HIV Australia, also strongly endorses urgent discussions to ensure PrEP is listed on the PBS as soon as possible. “PrEP keeps people at high risk of HIV safe and gives people control and confidence,” he said. “This helps everyone take responsibility for HIV prevention.”

Extremely effective at protecting against HIV, PrEP — pre-exposure prophylaxis — has shown to be a valuable tool in the arsenal to end new transmissions. Indeed, the UK PROUD study has shown that for every 13 people on PrEP, one HIV transmission is avoided. “Australia’s HIV rate has stubbornly plateaued at around 1,100 new infections per year for the past five years,” said O’Donnell. “With PrEP at the centre of a revived response, we would make serious inroads in ending HIV transmission. Without access to PrEP, Australia will not achieve its target of ending HIV transmission by 2020.”

latest news

May 9, 2018
The federal government's budget details were released last night. Here's a community response.
March 29, 2018
We’re not talking about recovery parties here, but the post-recovery recovery when the festivities have ended.
March 21, 2018
The world has lost one of the most respected scientists in the field of HIV/AIDS, Professor David Cooper.
March 21, 2018
The cost of PrEP (pre-exposure prophylaxis) is to be drastically reduced from 1 April
February 12, 2018
The annual awareness day on 9 March is aimed at encouraging women to test for HIV.
January 22, 2018
Once again, 9 March commemorates the National Day of Women Living with HIV Australia. 
November 30, 2017
On a trip to Bali, David Menadue discovered that it pays to be clued up about travel insurance.
November 30, 2017
Armistead Maupin talks to Steven Petrow about 1970s San Francisco, AIDS and ageing.
November 30, 2017
This year marks the 30th anniversary of the AIDS Memorial Quilt. Read the story behind the icon.
November 29, 2017
They are the all-too forgotten minority: heterosexual men with HIV. Here are their stories.
November 29, 2017
In 2018, researchers will explore a number of approaches that might bring an end to the need for treatment.
November 29, 2017
As people with HIV get older and live longer, they become vulnerable to cardiovascular disease. 
August 22, 2017
A decision to subsidise PrEP has been deferred, much to the disappointment and frustration of HIV advocates.
July 26, 2017
Results from an Australian study show that HIV-positive men on treatment cannot transmit the virus.
June 22, 2017
Why is an easily curable disease once believed to be on the wane in Australia out of control?